Early treatment response following Iodine-131 therapy in pediatric differentiated thyroid carcinoma and the prognostic value of thyroglobulin
Main Article Content
Abstract
This study was conducted to investigate the early response following the first I-131 treatment and determined the prognostic value of pre-therapeutic stimulated Thyroglobulin (Tg) levels in pediatric patients with differentiated thyroid cancer. 50 patients under 18 years of age at K Hospital from November 2019 to February 2026 were included in the investigation. The excellent response rate after the initial I-131 dose was 34.0%. Pre-therapeutic stimulated Tg levels significantly correlated with treatment outcomes, showing a clear downward trend in the excellent response rate as Tg levels increased (p < 0.001). Multivariate regression analysis identified Tg as an independent predictor of response. Furthermore, ROC analysis demonstrated that Tg has a strong discriminative capacity between response groups (AUC = 0.882; 95% CI: 0.791 - 0.974), with an optimal cutoff value of 7.30 ng/mL (sensitivity 88.2%, specificity 69.7%). In conclusion, pre-therapeutic stimulated Tg concentration is a valuable prognostic factor for predicting early response to I-131 therapy in pediatric patients with differentiated thyroid cancer.
Article Details
Keywords
Pediatric differentiated thyroid cancer, I-131, stimulated Thyroglobulin
References
2. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184-199. doi:10.1038/nrc3431
3. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
4. Hay ID, Johnson TR, Kaggal S, et al. Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936–2015). World J Surg. 2018;42(2):329-342. doi:10.1007/s00268-017-4279-x
5. Francis GL, Waguespack SG, Bauer AJ, et al. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015;25(7):716-759. doi:10.1089/thy.2014.0460
6. Lê Ngọc Hà. Điều trị và quản lý ung thư tuyến giáp thể biệt hóa sau phẫu thuật.Nhà xuất bản y học. 58-69. 230-244.
7. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi:10.1089/thy.2015.0020
8. Cistaro A, Quartuccio N, Garganese MC, et al. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study. Eur J Nucl Med Mol Imaging. 2022;49(4):1374-1385. doi:10.1007/s00259-021-05586-8
9. Zampella E, Piscopo L, Manganelli M, et al. Prognostic value of 12-month response to therapy in pediatric patients with differentiated thyroid cancer. Endocrine. 2023;80(3):612-618. doi:10.1007/s12020-023-03309-7
10. Nguyễn Thị Nhung, Lê Duy Hưng, Lê Ngọc Hà. Ung thư tuyến giáp ở bệnh nhân dưới 18 tuổi: đặc điểm xạ hình I-131 và kết quả sau điều trị I-131. Tạp chí Y Dược lâm sàng 108. 2018;13(special issue):134-140.
11. Wang C, Lu G, Li Y, et al. Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy. Front Endocrinol (Lausanne). 2023;14:1217092. doi:10.3389/fendo.2023.1217092
12. Jaeger F, Eidt LB, Guidolin K, et al. Is Stimulated Thyroglobulin Before Radioiodine Therapy a Useful Tool in Predicting Response to Initial Therapy in Patients with Differentiated Thyroid Carcinoma? Horm Metab Res. 2024;56(09):641-648. doi:10.1055/a-2318-5320